Pfizer posted preliminary results of its coronavirus vaccine study that it said triggered a 'strong immune response' in human trials.
Pfizer, and its partnering firm, Germany-based BioNTech Inc.now plan to test the most promising of its four vaccine candidates on up to 30,000 participants in trials set for the United States and Europe.
No serious adverse effects were reported in the study, Pfizer said, which included testing of two BNT1162b1 doses on 24 healthy patient volunteers, but those treated showed higher levels of COVID-19 antibodies when compared to those infected by the disease.
“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” said Dr. Kathrin Jansen, who heads vaccine research & development at Pfizer. “We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency. We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible.”
Per Pfizer, if regulators ultimately approve the drug he two companies plan to manufacture up to 100 million doses by the end of the year, and "at least" another 1.2 billion by the end of 2021.
But what should investors take away from the news around this vaccine? Here’s what Jim Cramer thinks.